Short-term, high dose enzyme replacement therapy in sialidosis mice

Molecular Genetics and Metabolism

Volumn 85, Issue 3, 2005, Pages 181-189

  Wang, Dongning ^a   Bonten, Erik J ^a   Yogalingam, Gouri ^a   Mann, Linda ^a   D'Azzo, Alessandra ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Baculovirus expression system; Enzyme replacement therapy; Lysosomal neuraminidase; Protective protein cathepsin A; Sialidosis

Indexed keywords

CARBOXYPEPTIDASE C; SIALIDASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; DRUG ABSORPTION; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME REPLACEMENT; HALF LIFE TIME; IMMUNE RESPONSE; IMMUNITY; IMMUNOPATHOLOGY; LYSOSOME STORAGE DISEASE; MACROPHAGE; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SHORT COURSE THERAPY; SIALIDOSIS;

ANIMALS; BACULOVIRIDAE; CARBOXYPEPTIDASE C; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GENE TARGETING; HUMANS; MICE; MICE, MUTANT STRAINS; MUCOLIPIDOSES; NEURAMINIDASE; RECOMBINANT PROTEINS;

INSECTA; MAMMALIA;

EID: 20544453493     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymgme.2005.03.007     Document Type: Article

References (40)

1. G.H. Thomas Disorders of glycoprotein degradation: α-mannosidosis, β-mannosidosis, fucosidosis, and sialidosis C.R. Scriver A.L. Beaudet W.S. Sly D. Valle The metabolic and molecular bases of inherited disease 2001 McGraw-Hill New York 3507 3534
2. R.O. Brady, and R. Schiffmann Enzyme-replacement therapy for metabolic storage disorders Lancet Neurol. 3 2004 752 756
3. P. Harmatz, C.B. Whitley, L. Waber, R. Pais, R. Steiner, B. Plecko, P. Kaplan, J. Simon, E. Butensky, and J.J. Hopwood Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) J. Pediatr. 144 2004 574 580
4. J.M. Van den Hout, A.J. Reuser, J.B. de Klerk, W.F. Arts, J.A. Smeitink, and A.T. Van der Ploeg Enzyme theraphy for Pompe disease with recombinant human alpha-glucosidase from rabbit milk J. Inherit. Metab. Dis. 24 2001 266 274
5. E.D. Kakkis, J. Muenzer, G.E. Tiller, L. Waber, J. Belmont, M. Passage, B. Izykowski, J. Phillips, R. Doroshow, I. Walot, R. Hoft, and E.F. Neufeld Enzyme-replacement therapy in mucopolysaccharidosis I N. Engl. J. Med. 344 2001 182 188
6. R. Schiffmann, J.B. Kopp, H.A. Austin III, S. Sabnis, D.F. Moore, T. Weibel, J.E. Balow, and R.O. Brady Enzyme replacement therapy in Fabry disease: a randomized controlled trial J. Am. Med. Assoc. 285 2001 2743 2749
7. G.A. Grabowski, N. Leslie, and R. Wenstrup Enzyme therapy for Gaucher disease: the first 5 years Blood Rev. 12 1998 115 133
8. H. Van den Hout, A.J. Reuser, A.G. Vulto, M.C. Loonen, A. Cromme-Dijkhuis, and A.T. Van der Ploeg Recombinant human alpha-glucosidase from rabbit milk in Pompe patients Lancet 356 2000 397 398
9. J.L. Van Hove, H.W. Yang, J.Y. Wu, R.O. Brady, and Y.T. Chen High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease Proc. Natl. Acad. Sci. USA 93 1996 65 70
10. U. Matzner, A. Hille-Rehfeld, F.K. von, and R. Pohlmann Expression of mannose-6-phosphate receptors in chicken Dev. Dyn. 207 1996 11 24
11. Z. Liu, D.W. Mittanck, S. Kim, and P. Rotwein Control of insulin-like growth factor-II/mannose-6-phosphate receptor gene transcription by proximal promoter elements Mol. Endocrinol. 9 1995 1477 1487
12. P. Nissley, W. Kiess, and M. Sklar Developmental expression of the IGF-II/mannose-6-phosphate receptor Mol. Reprod. Dev. 35 1993 408 413
13. B. Funk, U. Kessler, W. Eisenmenger, A. Hansmann, H.J. Kolb, and W. Kiess Expression of the insulin-like growth factor-II/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy J. Clin. Endocrinol. Metab. 75 1992 424 431
14. U. Matzner, F.K. von, and R. Pohlmann Expression of the two mannose-6-phosphate receptors is spatially and temporally different during mouse embryogenesis Development 114 1992 965 972
15. M.M. Sklar, W. Kiess, C.L. Thomas, and S.P. Nissley Developmental expression of the tissue insulin-like growth factor II/mannose-6-phosphate receptor in the rat. Measurement by quantitative immunoblotting J. Biol. Chem. 264 1989 16733 16738
16. G.A. Grabowski, N.W. Barton, G. Pastores, J.M. Dambrosia, T.K. Banerjee, M.A. McKee, C. Parker, R. Schiffmann, S.C. Hill, and R.O. Brady Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources Ann. Intern. Med. 122 1995 33 39
17. M.S. Sands, C.A. Vogler, K.K. Ohlemiller, M.S. Roberts, J.H. Grubb, B. Levy, and W.S. Sly Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII J. Biol. Chem. 276 2001 43160 43165
18. E.J. Bonten, D. Wang, J.N. Toy, L. Mann, A. Mignardot, G. Yogalingam, and A. d'Azzo Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis FASEB J. 18 2004 971 973
19. A. d'Azzo, G. Andria, P. Strisciuglio, and H. Galjaard Galactosialidosis C.R. Scriver A.L. Beaudet W.S. Sly D. Valle The metabolic and molecular bases of inherited disease 2001 McGraw-Hill New York 3811 3826
20. N. de Geest, E. Bonten, L. Mann, J. de Sousa-Hitzler, C. Hahn, and A. d'Azzo Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice Hum. Mol. Genet. 11 2002 1455 1464
21. A. van der Spoel, E. Bonten, and A. d'Azzo Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A EMBO J. 17 1998 1588 1597
22. E.J. Bonten, and A. d'Azzo Lysosomal neuraminidase. Catalytic activation in insect cells is controlled by the protective protein/cathepsin A J. Biol. Chem. 275 2000 37657 37663
23. G. Rudenko, E. Bonten, A. d'Azzo, and W.G. Hol Three-dimensional structure of the human 'protective protein': structure of the precursor form suggests a complex activation mechanism Structure. 3 1995 1249 1259
24. H. Galjaard Genetic metabolic disease: Diagnosis and prenatal analysis 1980 Elsevier Science Publishers Amsterdam
25. T. Ono, and R.S. Tuan Double staining of immunoblot using enzyme histochemistry and India ink Anal. Biochem. 187 1990 324 327
26. E. Monti, A. Preti, B. Venerando, and G. Borsani Recent development in mammalian sialidase molecular biology Neurochem. Res. 27 2002 649 663
27. R.J. Desnick Enzyme replacement and enhancement therapies for lysosomal diseases J. Inherit. Metab Dis. 27 2004 385 410
28. S.H. Cheng, and A.E. Smith Gene therapy progress and prospects: gene therapy of lysosomal storage disorders Gene Ther. 10 2003 1275 1281
29. M.A. Cabrera-Salazar, E. Novelli, and J.A. Barranger Gene therapy for the lysosomal storage disorders Curr. Opin. Mol. Ther. 4 2002 349 358
30. E.D. Kakkis, E. Schuchman, X. He, Q. Wan, S. Kania, S. Wiemelt, C.W. Hasson, T. O'Malley, M.A. Weil, G.A. Aguirre, D.E. Brown, and M.E. Haskins Enzyme replacement therapy in feline mucopolysaccharidosis I Mol. Genet. Metab. 72 2001 199 208
31. K. Knowles, J. Alroy, M. Castagnaro, S.S. Raghavan, R.M. Jakowski, and G.O. Freden Adult-onset lysosomal storage disease in a Schipperke dog: clinical, morphological and biochemical studies Acta Neuropathol. (Berl.) 86 1993 306 312
32. J.C. Woloszynek, M. Roberts, T. Coleman, C. Vogler, W. Sly, C.F. Semenkovich, and M.S. Sands Numerous transcriptional alterations in liver persist after short-term enzyme-replacement therapy in a murine model of mucopolysaccharidosis type VII Biochem. J. 379 2004 461 469
33. E. Kakkis, M. McEntee, C. Vogler, S. Le, B. Levy, P. Belichenko, W. Mobley, P. Dickson, S. Hanson, and M. Passage Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I Mol. Genet. Metab. 83 2004 163 174
34. D.A. Brooks Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models Mol. Genet. Metab. 68 1999 268 275
35. C.T. Turner, J.J. Hopwood, C.S. Bond, and D.A. Brooks Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats Mol. Genet. Metab. 67 1999 194 205
36. D.A. Brooks, J.J. Hopwood, and B.M. King Immune response to enzyme replacement therapy: clinical signs of hypersensitivity reactions and altered enzyme distribution in a high titre rat model Biochim. Biophys. Acta 1407 1998 163 172
37. D.A. Brooks, R. Kakavanos, and J.J. Hopwood Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder Trends Mol. Med. 9 2003 450 453
38. E. Bonten, S.A. van der, M. Fornerod, G. Grosveld, and A. d'Azzo Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis Genes Dev. 10 1996 3156 3169
39. E.J. Bonten, W.F. Arts, M. Beck, A. Covanis, M.A. Donati, R. Parini, E. Zammarchi, and A. d'Azzo Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis Hum. Mol. Genet. 9 2000 2715 2725
40. E. Kakkis, T. Lester, R. Yang, C. Tanaka, V. Anand, J. Lemontt, M. Peinovich, and M. Passage Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I Proc. Natl. Acad. Sci. USA 101 2004 829 834